Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- -
Safety Study of Interferon Beta 1a to for Acute Stroke
- Conditions
- Cerebrovascular Accident
- First Posted Date
- 2004-11-22
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Target Recruit Count
- 60
- Registration Number
- NCT00097318
- Locations
- 🇺🇸
Washington Hospital Center, Washington, D.C., District of Columbia, United States
🇺🇸Suburban Hospital, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis
- First Posted Date
- 2002-10-30
- Last Posted Date
- 2010-09-08
- Target Recruit Count
- 18
- Registration Number
- NCT00048347
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00037102
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
- Conditions
- Demyelinating DisordersMultiple SclerosisOptic NeuritisMyelitisNeuritis
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
- Registration Number
- NCT00037115
- Locations
- 🇺🇸
MidAmerica Neuroscience Institute, Kansas City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.